header logo image


Page 4«..3456..1020..»

Archive for the ‘Immune System’ Category

Study raises concerns about the effectiveness of the monkeypox vaccine – STAT

Sunday, September 4th, 2022

A new study is raising concerns about the effectiveness of the monkeypox vaccine being used in the United States and other parts of the world.

The work, which has not yet been peer-reviewed, found that two doses of the vaccine induced relatively low levels of neutralizing antibodies against the monkeypox virus, and those antibodies had poor neutralizing capacity.

The researchers noted the so-called correlates of protection what is needed, in terms of immune system weaponry, to be protected against monkeypox are not known. Still, the evidence of low levels of neutralizing antibodies raises questions about how much protection is generated by two doses of the vaccine, marketed as Jynneos in the U.S. and made by the Danish manufacturer Bavarian Nordic.

advertisement

At this moment it is unclear what the relatively low [monkeypox virus] neutralizing titers mean for protection against disease and transmissibility, the researchers, from Erasmus Medical Center in Rotterdam, the Netherlands, wrote.

But one of the senior authors of the paper said what is clear is that people being administered this vaccine ought to be cautious about assuming they are protected against infection.

advertisement

The expectation is not that this will provide sterilizing immunity, said Marion Koopmans, who heads Erasmus department of viroscience, referring to the type of immunity that will block infection.

Koopmans added that controlling the outbreak will require a suite of transmission-reducing tools, including isolation of cases, tracing and quarantining of contacts, and vaccination of people who have been exposed to the virus or are at high risk of exposure.

Inger Damon, who heads the division of high-consequence pathogens and pathology at the Centers of Disease Control and Prevention, said that studying how much protection the vaccine offers is critical, especially given that many of the people contracting it may be becoming infected via exposure of mucus membranes to infectious lesions. Mucus membranes are more delicate than skin, potentially allowing a larger dose of virus to infect an exposed individual.

I think this is something that we have to very carefully follow, and we need to really be very forthright in helping the community who is at risk to understand what the limitations of our knowledge is, Damon told STAT earlier this week in an interview.

On Friday, she said Koopmans had shared the data in the study with the CDC before it was posted online.

Foundational to all of this will be to understand the progression of disease and the immune response to disease with the different routes of infection that we believe we are seeing, Damon said in an email. This is complicated, and will require concerted, coordinated, and collaborative efforts to find the right solutions to stop the spread of disease. Good health communications, and effective harm reduction messages are going to be integral.

The Erasmus study suggests, among other things, that a one-dose regimen seems to be inadequate to induce protection.

The second vaccination is important for reaching detectable antibody levels, as individuals in a single-shot regimen hardly developed antibody responses four and eight weeks after vaccination, the researchers wrote.

The study also casts a shadow over the recent decision by the U.S. government and others to stretch vaccine supplies by giving people one-fifth of a regular dose and to do so by intradermal (into the skin) rather than subcutaneous (under the skin) injection. Intradermal administration, which requires smaller doses to be protective, has been shown to be effective in other disease outbreaks with other types of vaccine.

The decision to use this dose-sparing approach which allows up to five people to be vaccinated with the amount of vaccine normally used for one was largely based on a small study that compared immune responses generated by two fractional doses given intradermally to two full doses given subcutaneously. They were deemed to be comparable.

But Koopmans and her colleagues saw another result in an earlier Erasmus study that tested fractional doses of a bird flu vaccine using the same vaccine backbone as the Bavarian Nordic product.

Jynneos uses a modified vaccinia virus called MVA, the same attenuated virus formerly used to vaccinate against the now-eradicated smallpox to teach the immune system to be on guard for monkeypox, a related virus.

The same MVA backbone was used in an experimental vaccine to protect against H5N1 bird flu. There, the two fractional doses generated lower amounts of antibodies than the full doses did, the researchers reported.

This same trial indicates that dose-sparing has a negative effect on the serological outcome of vaccination, they wrote.

It should be noted that in that trial, the fractional doses were administered by intramuscular injections, not intradermal. Koopmans said the group is planning to test whether intradermal vaccine administration would improve results, once it has been cleared to conduct the study.

Asked if she thought public health authorities should rethink giving fractional doses of monkeypox vaccine, she wrote: I think it requires testing.

So does Michael Osterholm, director of the University of Minnesotas Center for Infectious Diseases Research and Policy. Osterholm thought the move to fractional dosing was made too quickly, based on too little data.

I realize in a public health crisis, sometimes you have to make decisions with imperfect information, he said after reading the Erasmus study. But this is the kind of data that I think everyone needs to take a step back now and say: What does this mean for what were doing right now?

They dont have a lot of other tools, he acknowledged. But at the same time, if the tool youre using isnt adequate to do the job, then you have to consider that. Do we need to go back to full dose?

Osterholm and others expressed concern that people getting the vaccine will conclude they have a level of protection that they may not have.

See the rest here:
Study raises concerns about the effectiveness of the monkeypox vaccine - STAT

Read More...

Five Natural Immune-Boosting Treatments to Try This Flu Season – Boston magazine

Sunday, September 4th, 2022

Guides

This cold and flu season, dont just douse yourself in hand sanitizer. Fight germs with local treatments designed to boost the bodys natural defenses.

Illustration by Jeannie Phan

For a Spin in an Infrared SaunaThe Indoor Oasis

From soaking up the sun on your favorite beach down on the Cape to perfecting the camel pose in your weekly hot yoga class, youre not afraid to break a sweat. Put your tolerance for heat to good use at the Indoor Oasis in Newton, where you can book 20- and 40-minute sessions in a private infrared sauna. Unlike a traditional sauna, which uses steam to warm the air, infrared models rely on heat lamps or light panels to raise your body temperaturepromising to ease joint pains, increase circulation, and (according to some studies) help you ward off the common cold in the process.

theindooroasis.com.

For IV TherapyVita Hydration + Wellness

Not one to panic at the sight of a needle? The trendy IV-powered services at this Worcester-based wellness center should suit you just fine. In particular, the teams Immunity drip is packed with vitamins B and C as well as the mineral zinc to help naturally strengthen your immune system and boost energy. Right arm or left?

vitahydrationandwellness.com.

For Red-Light TherapyRestore Hyper Wellness

Skin-care enthusiasts, take note: Red-light therapy isnt just known to strengthen the bodys disease-fighting resources. Some research suggests that the non-invasive treatmentwhich stimulates production of cell-repairing nitric oxide by harnessing the power of low-intensity LEDsmay combat wrinkles, scars, and sun damage, too. Give it a go at Restore Hyper Wellness. With locations in Newton and Hingham (and new spots on the way in Woburn and Dedham), the spas single-user red-light therapy rooms are prime spots for donning your sunglasses and basking in the scarlet glow.

restore.com.

For Salt TherapyScituate Salt Cave

We all know that filling our bellies with too much high-sodium food can wreak havoc on our kidneys and blood pressure. But spending time in the company of 30,000 pounds of Himalayan pink salt, which has anti-inflammatory properties? Thats another story. At this recently opened spot in Scituate, you can book 45-minute sessions in your choice of two salt caveseach designed to help you relax while you inhale the mineral-rich air (and rid your airways of any illness-causing intruders while youre at it).

scituatesaltcave.com.

For Lymphatic DrainageG2O Spa + Salon

Charged with producing infection-battling white blood cells, the lymphatic system is a critical component of your bodys immune response. Give it the attention it deserves with G2Os 60-minute body lymphatic drainage treatment, during which a technician moves a vacuum-like device over the back, legs, and abdomen to help alleviate any swelling or blockages in the system that may affect its performance, as well as reduce everyday annoyances like bloating and fatigue.

g2ospasalon.com.

More:
Five Natural Immune-Boosting Treatments to Try This Flu Season - Boston magazine

Read More...

Returning to Football After COVID-19 Infection – Louisiana State University

Sunday, September 4th, 2022

BATON ROUGE - A first-of-its-kind study conducted in collaboration with LSUs School of Kinesiology, LSU Athletics, Pennington Biomedical Research Center and Our Lady of the Lake researched how the immune system of elite student-athletes responded to the COVID-19 virus.

New collaborative study shows LSU Football players bounced back quickly from COVID-19 following the CDC's recommended amount of isolation time.

Photo: LSU Athletics

The football players who were diagnosed with COVID-19 were able to have their immune system back to its baseline after the CDC-recommended isolation. This is in stark contrast with older adults with comorbidities, who tend to be more at riskfor serious side effects and symptoms, and even death.

When COVID-19 really started moving out of control, we met with Neil Johannsen, an exercise physiologist at LSU, and the athletic trainers Derek Calvert and Jack Marucci, and we discussed what we could do to make sure our athletes remained healthy. We especially wanted to make sure that athletes were not at risk for secondary infections when they came back from isolation, said Guillaume Spielmann, associate professor in LSU's School of Kinesiology.

When the idea started for the research, we discussed why not turn something negative into a positive, and assist with the research to find some answers. If we can do things to understand the virus better, lets do it, said Jack Marucci, LSUs Director of Athletic Training. The student-athletes were willing to be a part of it.

During that time at the start of the COVID pandemic, the CDC had recommended 14 days of isolation.

There was a lot unknown during this time. We are looking at a population that are extremely close to each other during plays and during games. We wanted to make sure that since they are literally face-to-face with other players, that their salivary defenses, their oral defenses were pretty much intact and that that part of their immune system was not affected by the disease; that there were no long-lasting effects of the disease, Spielmann said.

Saliva samples were collected from 29 student-athletes in 2020, before a COVID vaccine. Fourteen were COVID positive and 15 had no history of infection. Of the 14, only six reported mild symptoms from the virus, the other eight were asymptomatic throughout the isolation period.

Salivary immunity is extremely important to ensure that people dont contract secondary infections, so when athletes are coming back we need to make sure they are as healthy as can be. We found that the isolation period was sufficient to restore the athletes salivary immunity to the level seen in non-infected players, Spielmann said.

These findings suggested the student-athletes could safely return to practice and play football without a risk of secondary infection; that their immune system wasnt at risk when playing the close contact sport.

I was worried a bit about long-haulers and other more significant outcomes like the concerns for the development of myocarditis. Engaging in athletic activities at an elite level can be stressful on the body and you would want to arm yourselves with the best scientific information to help understand potential outcomes. This data helped to validate some of these decisions that were made. Providing a safe environment for your student-athletes is paramount and this helped that process along, said Shelly Mullenix, LSU's Senior Associate Athletics Director for Health & Wellness.

For this study, three graduate students also participated in the research. Their research is now published in Scientific Reports.

This kind of access is unique in Division I sports. You typically dont have access to football players, so the fact that we have access is hugely instrumental as well, Spielmann said. LSU is a great place for this field.

I think this COVID research is something that we are really proud to be a part of and contribute to finding answers to such a devastating virus, Marucci said.

Spielmann, an immunologist, researches the impact of stress on the immune system of elite and tactical athletes, including astronauts and fire fighters.But this study isnt the first for Spielmann and LSU Athletics. They have worked together to study psychological and physiological health, along with performance measures in other student-athletes and sports teams.A new study will take a closer look at female athletes mental, physiological and immune resilience to stress. Funded by a grant from the Wu Tsai Foundation, this collaborative research led by Tiffany Stewart at Pennington Biomedical and Spielmann will include participation from 50 LSU female athletes.

These groups also work together as part of the healthcare partnership with Our Lady of the Lake. Our Lady of the Lake has committed $170 million over the next 10 years for academics- and athletics-focused initiatives. Dr. Catherine O'Neal, Chief Medical Office of Our Lady of the Lake said this partnership allows for increased collaboration and research between LSU and Our Lady of the Lake, as well as Pennington Biomedical Research Center.

Original post:
Returning to Football After COVID-19 Infection - Louisiana State University

Read More...

#1 Best Way to Boost Your Immunity Against BA.5 Eat This Not That – Eat This, Not That

Sunday, September 4th, 2022

Nature has thrown at us many challenges throughout our existence. This time around it is a novel coronavirus that has led to a global pandemic. When facing an infectious disease, like COVID-19, how healthy and robust our immune system is plays a pivotal role in how our body can defend itself from infection. With COVID-19, we've seen how it's adapted and transformed to survive and bypass our immune defenses. Therefore, having a healthy immune system that can quickly adapt and respond to such a threat is important. The newest transformation of COVID is known as variant BA.5. This omicron subvariant has become the predominant strain in the US as of July 2022. Its mutations have made it possible for it to infect people who are vaccinated and/or have had a recent COVID infection.

The healthier we areboth mentally and physicallythe easier we can adapt and respond to threats in our surroundings. A person in good physical health is more likely to outrun someone who is trying to do them harm than someone who is unhealthy. Unfortunately, we cannot outrun a threat like COVID no matter how healthy we are, but we can take steps to help our bodies protect themselves against possible infection. It requires all of our mental and physical health when facing a virus like COVID. Physical health is not only about having lean healthy muscle mass, but also having an immune system that can face the ever-changing threat of a mutating virus.Jimmy Salas Rushford, MD is a Medical Director Protocol Architect of FiTBodyMD.

As research continues to advance human immunity, the importance of polysaccharides obtained from natural edible sources has gained significant traction. Natural foods like mushrooms and fruits are filled with polysaccharides. One of the key factors in building a robust and healthy immune system is by maintaining a diet filled with natural whole foods and/or incorporating daily supplements.

Polysaccharides found in some sea weeds have shown promise for antiviral properties. Another promising supplement is AHCC which is a cultured extract from the roots of a Japanese mushroom. AHCC has been shown by numerous human clinical studies to help the body's immune system recognize and fight pathogens such as viruses and bacteria.

If we want to be ready for health threats like COVID, we should prepare our body to recognize and have the resources to fight infection before it gains access to our body and then outsmart those pathogens in order to prevent future infection.

In addition to ensuring we're taking the right supplement(s) to boost immunity, there are a few more steps we can take to protect ourselves from infection. In my experience, I've learned that it is better to do a few things extremely well than many things poorly. By concentrating on a few key points and making consistent habits, we can ensure the greatest results.

We've heard time and again that sleep is not only important to our mental health but to our physical health as well. It plays a huge role in how our body can protect itself from disease/infection. The National Sleep Foundation advises that healthy adults need between 7 and 9 hours of sleep per night. Research has shown that sleep deficiency is linked to many chronic health problems. Thus, adequate sleep is a must.

Rely on trusted sources and not just a Google search. When seeking out information to protect your health, find trusted and reliable sources of information such as a medical practitioner or information backed by medical institutions, practitioners, or research. For example, when searching for dietary modifications and supplement recommendations, look for sources backed by human clinical data and reputable researchers and institutions.

Vitamin D is another example of a nutrient that has been shown to boost immunity. Vitamin D's effect goes far beyond just helping our body with calcium homeostasis and bone health. Vitamin D also regulates many other cellular functions in your body. Its anti-inflammatory, antioxidant and neuroprotective properties support immune health, muscle function and brain cell activity.6254a4d1642c605c54bf1cab17d50f1e

Eating whole foods and achieving daily physical activity are of upmost importance in maintaining good health. The pandemic has helped us realize that physical health is only a part of the puzzle when preparing our bodies to fight COVID and future infections. Although our immune system is one that has evolved over millennia and is extremely complex, it only takes a few basic healthy routines to keep it in tip top shape. Let's start by eating whole foods and vegetables, choosing vitamins and supplements backed by reputable clinical data, achieving consistent physical activity and reducing our stress.

Read the original post:
#1 Best Way to Boost Your Immunity Against BA.5 Eat This Not That - Eat This, Not That

Read More...

Non-Hodgkin’s lymphoma: What is the cancer that Jane Fonda announced she has? – FOX 29 Philadelphia

Sunday, September 4th, 2022

Jane Fonda announced on Friday that she is suffering from non-Hodgkin's lymphoma a type of cancer that can start anywhere in the body where lymph tissue is located. (Getty Images)

Two-time Academy Award winnerJane Fonda announced on Instagram on Friday that she's been diagnosed with a treatable form ofnon-Hodgkins lymphoma.

"So, my dear friends, I have something personal I want to share," the 84-year-old wrote.

"Ive been diagnosed with non-Hodgkins lymphoma and have started chemo treatments," Fonda also said.

Cancer occurs when cells in the body grow out of control, according to the American Cancer Society. Almost any cell in the human body can become cancerous and spread to other parts of the body, the same source also explained.

JANE FONDA ANNOUNCES CANCER DIAGNOSIS: VERY TREATABLE

But what is non-Hodgkins lymphoma, exactly?

Non-Hodgkin's lymphoma (NHL) is a type of cancer that begins in theimmune system.

Jane Fonda (Photo by Tommaso Boddi/WireImage )

The immune system helpsfight infection, but sometimes a cancer can start in the white blood cells called lymphocytes and cause non-Hodgkins lymphoma, the society added.

It is a general term that is used for many types of lymphoma that occurs most often in adults, per the association.

Approximately 2% of men and women will be diagnosed with non-Hodgkin's lymphoma at some point during their lifetime, according to the National Cancer Institute's data from 2017-2019.

The institute estimates that 763,401 people were living with non-Hodgkin's lymphoma in the United States in 2019.

"Lymphomas can start anywhere in the body where lymph tissue is found," according to the American Cancer Societys website.

Jane Fonda (Photo by Caroline McCredie/Getty Images for Chopard)

These include lymph nodes, which are small, bean-shaped structures that are connected by a network of lymphatic vessels.

They're located throughout the body, such as inside the chest and abdomen and pelvis. Lymph tissue is also found in the spleen, bone marrow, thymus, tonsils and digestive tract.

Symptoms include fever, night sweats and weight loss as well as a swelling of lymph nodes in the neck, armpit or groin, according to the Mayo Clinic.

Patients may feel persistent fatigue, coughing, shortness of breath or chest pain.

"The lymph system is made up mainly of lymphocytes, a type of white blood cell that helps the body fight infections," according to the American Cancer Societys website.

There are two types of lymphocytes: B cells or T cells.

Actress Jane Fonda is seen outside "GMA" on July 19, 2022 in New York City. (Photo by Raymond Hall/GC Images)

B cells help the body fight germs by creating antibodies which in turn help the body neutralize them.

"There are several types of T cells. Some T cells destroy germs or abnormal cells in the body," according to the American Cancer Society.

"Other T cells help boost or slow the activity of other immune system cells."

Although lymphoma can start in either type of cell line, B-cell lymphomas are most common.

Lymphocytes usually go through a life cycle, in which old lymphocytes die and then the body replaces them.

"In non-Hodgkin's lymphoma, your lymphocytes don't die, and your body keeps creating new ones," according to the Mayo Clinics website.

Jane Fonda is shown posing for a publicity shot in 1967. She wrote on Instagram this week that she "will not allow cancer to keep me from doing all I can, using every tool in my toolbox." (Bettmann/Contributor via Getty Images)

"This oversupply of lymphocytes crowds into your lymph nodes, causing them to swell."

Lymphomas also can be categorized by how fast they grow and spread to other parts of the body.

Some are known as "indolent," which means they grow and spread slowly, so they might not need to be treated when first diagnosed.

"The most common type of indolent lymphoma in the United States is follicular lymphoma," according to the American Cancer Society.

Aggressive lymphomas, however,grow and spread rapidly, so treatment is often started immediately.

"The most common type of aggressive lymphoma in the United States is diffuse large B cell lymphoma," per the American Cancer Society. "Regardless of how quickly they grow, all non-Hodgkin lymphomas can spread to other parts of the lymph system if not treated."

Eventually, they can also spread to other parts of the body.

STUDY SUGGESTS ALCOHOL AND SMOKING CAUSE ALMOST HALF OF GLOBAL CANCER DEATHS

The overall five-year relative survival rate for NHL is 73.8%, per the National Cancer Institute's 2012 to 2018 data.

Fonda posted on Instagram that she feels lucky because she has a "very treatable cancer" with an 80% survivable rate, although she did not specify the exact type she has.

Some people are more at risk for NHL, including those who take medications to depress the immune system and patients with certain viral infections, such as HIV or the virus that can cause mononucleosis known as Epstein-Barr virus, according to the Mayo Clinic.

The cancer is also associated with the bacteria Helicobacter pylori, which causes stomach ulcers as well as certain chemicals that are used to kill insects and weeds, per Mayo Clinic.

NEW STUDY SUGGESTS YOU SHOULD STOP EATING ULTRA-PROCESSED FOODS

And people over the age of 60 are at higher risk, although anyone can get the cancer, per Mayo Clinic.

"Im doing chemo for six months and am handling the treatments quite well and, believe me, I will not let any of this interfere with my climate activism," said Fonda, who is also an advocate for environmental issues.

Actress Jane Fonda is arrested during the "Fire Drill Friday" Climate Change Protest on October 25, 2019 in Washington, DC . (Photo by John Lamparski/Getty Images)

She was inspired bySwedish environmental activistGreta Thunberg in 2019, she said, to become an advocate for the climate change, starting "Fire Drill Fridays" to raise awareness of environmental challenges, according to her website.

She was arrested multiple times that year after organizing protests on the climate crisis inWashington, D.C, according to The New York Times.

Fonda posted on Instagram that she"will not allow cancer to keep me from doing all I can, using every tool in my toolbox, and that very much includes continuing to build this Fire Drill Fridays community and finding new ways to use our collective strength to make change."

LINK: Get updates and more on this story at foxnews.com.

More here:
Non-Hodgkin's lymphoma: What is the cancer that Jane Fonda announced she has? - FOX 29 Philadelphia

Read More...

Whatever happened to the Botswana scientist who identified omicron then caught it? – NPR

Sunday, September 4th, 2022

Sikhulile Moyo, the laboratory director at the Botswana-Harvard AIDS Institute and a research associate with the Harvard T.H. Chan School of Public Health, headed the team that identified the omicron variant. Leabaneng Natasha Moyo hide caption

Sikhulile Moyo, the laboratory director at the Botswana-Harvard AIDS Institute and a research associate with the Harvard T.H. Chan School of Public Health, headed the team that identified the omicron variant.

Sikhulile Moyo led the team of scientists that first identified the omicron variant of COVID-19 in November 2021. It's gone on to dominate the world. Moyo directs the laboratory for the BotswanaHarvard AIDS Institute and is a research associate with the Harvard School of Public Health.

About This Series

Over the next week, we'll be looking back at some of our favorite Goats and Soda stories to see "whatever happened to ..."

Moyo was disturbed to see the world's reaction to the more transmissible variant. Other nations closed off travel and trade with southern African countries, including Botswana, even as they discovered the variant was already within their own borders. In fact, it was subsequently found that the variant was circulating in the Netherlands a week before the announcement from Africa.

"How do you reward the countries that alert you of a potential dangerous pathogen with travel bans? My country was put on a red list, and I didn't feel good about that," Moyo told NPR.

NPR touched base with Moyo to see what he's been working on and thinking about since this landmark discovery.

This interview has been edited for length and clarity.

You discovered omicron. Did omicron discover you?

I got COVID. Funnily enough, the omicron discoverer gets omicron.

I had three days of very serious symptoms of COVID, and I had to stay at home. So I would say mild to severe, but not too severe.

Then I had long COVID. I had almost three months of difficulty trying to recover my lung volume, my breathing. Walking, I was fatigued. All of a sudden, the COVID made my [blood] sugar worse, and I had to change my diabetes doses. I had to step up my meds, because it was no longer controlling [my diabetes] the way it was.

These are the complications that come with COVID, while people think COVID is gone.

Do you think the world has made any progress in learning not to cast blame?

There was a global awakening. Those events around the omicron discovery showed us the triumph of science but the failure of global health policy.

While we suffered, we were a catalyst to make people aware of the value of global public health that we cannot be inward-looking, because the virus knows no borders.

You see the response to monkeypox is different than the response to COVID. No one is blacklisting anyone from the monkeypox-endemic areas.

Has your work changed because of this discovery are you and your lab collaborating more with scientists around the world?

Yes! We have established collaborations with the Africa CDC. We've established what is called the Pathogen Genomics Initiative, a network of labs that are working together, and we have a lot of demand for training.

I was named one of the TIME magazine's 100 most influential people of 2022. That gives us a voice to share our experiences but also access to a lot of collaborations that I never thought I would have. That is really pushing us forward.

Have you made more ground-breaking omicron discoveries?

Earlier this year, around April, May, there was the discovery of BA.4 and BA.5, and we detected them in Botswana a few days after South Africa detected them. And these are the variants that have taken over the world. Some of the questions have been: What's happening in southern Africa that [the region] is seemingly detecting more variants?

What is unique about southern Africa, especially Botswana and South Africa, is the ability to detect these variants in near real-time because of the pathogen genomic sequencing that has been established [examining DNA to identify it or see if it's changing]. We think it's not that they are not circulating elsewhere, but it's just that maybe we are looking deeper.

We are always doing pathogen genomic sequencing. The most resourced in the world, in terms of sequencing, is of course the U.K. and the United States, and many parts of Europe. But I think the systematic, real-time, sampling and sequencing [in southern Africa] has been very, very useful.

How has southern Africa become so good at finding new variants and subvariants?

Southern Africa was the hotspot for HIV. We have passed through difficult times. I think we have taken this to our advantage to find solutions for ourselves. With funding from PEPFAR and from other international agencies, U.S. institutes, some donors southern Africa began to implement pathogen genomics focusing on HIV.

Some of us were involved in setting up population-based sequencing to understand the movement of viruses, to characterize transmission dynamics and that has spilled out to malaria, to TB. And we used those technologies to quickly adapt to SARS-CoV-2. That has been the strength of southern Africa.

We're even thinking beyond COVID. We are preparing ourselves to be able to adapt for pathogen discovery. If a [new] outbreak happens, we should be able to quickly check within 24 to 36 hours what it is.

New subvariants seem to be getting better at reinfecting people. What does that mean moving forward?

BA.4 and BA.5 are masters in terms of evading the fury of the immune system. The subvariants were able to elicit an immune response, but magnitudes lower than what we saw before.

As the immunity wanes down, that's where my worry is: How far can we hold on with the current levels of immunity?

The vaccine immunity still provides some protection against severe disease. We know that you may get infected, but you may not get hospitalized with BA.4 and BA.5.

It may get a little bit rough. Many people are spending days at home and [developing] long COVID afterward.

What do you think needs to happen next?

Research, training and development cost a lot of money, but as cases go down, people forget that we need to make sure these systems are sustained. That's one of the challenges: Are we going to be able to sustain some of this innovation that we have developed over a very difficult time of our lives during COVID?

The virus is still finding some pathways to escape immune pressure.

And there's always a possibility of a more virulent variant?

The variant that is going to really dominate is a variant that would have a massive escape to antibody neutralization or to vaccine neutralization. Chances are low of that happening. But omicron taught us that anything can happen.

So we need to be very careful. We need to continue with surveillance, so that if we notice anything, we should be able to go back and say: Do we need to change the way we are doing things?

While I support loosening and going back to our lives [when cases are low], I also feel that's when you need to be more vigilant. When you see signs of wildfire starting, then you can try and put it out.

Melody Schreiber (@m_scribe) is a journalist and the editor of What We Didn't Expect: Personal Stories About Premature Birth.

See original here:
Whatever happened to the Botswana scientist who identified omicron then caught it? - NPR

Read More...

8 Health Benefits of Cabbage – Health Essentials

Sunday, September 4th, 2022

Cabbage may not be the most attractive vegetable, but its full of nutritional goodness that can keep you feeling strong and healthy. From boosting your immune system to improving your digestion (sometimes with embarrassing results), cabbage and its health benefits deserve a place at your table.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services.Policy

This common leafy green vegetable comes in a range of colors, shapes and sizes that you can use for soups, salads, sandwiches and more. Eat it raw or stir-fried to get the most benefit. Find it fermented in gut-healthy foods like sauerkraut and kimchi or chopped into coleslaw for a quick fix.

Cabbage is good for you. Its one of those foods that tastes better than it looks, and it has even more nutritional value than people expect, says registered dietitian Julia Zumpano, RD, LD. Plus, its versatile, affordable and easy to find.

Zumpano explores the benefits of eating cabbage and how it can boost your health.

Many people recognize cabbage for its bounty of fiber, vitamins and minerals. One cup of chopped, raw green cabbage is only 22 calories and delivers:

Cabbage is also a potassium-rich food, which can help lower high blood pressure, says Zumpano. The more we learn about cabbage, the better it promises to be.

Research shows leafy green vegetables, in general, are good for you, but we need more studies to understand how cabbage specifically affects your body. Zumpano says many people believe the nutritional value of cabbage means it can have any of the following benefits.

Some of cabbages health benefits are due to anthocyanins, which are naturally occurring antioxidants. Anthocyanins not only add color to your fruits (think blueberries) and vegetables, but may also reduce inflammation.

Chronic inflammation (long-term swelling) is associated with heart disease, cancer, rheumatoid arthritis and many other medical conditions. In animal studies, anthocyanins have been shown to help control inflammation.

We need more research, but one small human study showed that those who ate the most cruciferous vegetables had much lower inflammation levels than those who ate the least.

Vitamin C, also known as ascorbic acid, does a lot of work for your body. It helps make collagen and boosts your immune system. It also helps your body absorb iron from plant-based foods.

Packed with phytosterols (plant sterols) and insoluble fiber, cabbage can help keep your digestive system healthy and bowel movements regular. It fuels the good bacteria in your gut that protects your immune system and produces essential nutrients. Thats especially true when you eat fermented cabbage in kimchi or sauerkraut.

Cabbage can help you stay regular, says Zumpano. It can also help support safe and healthy weight loss.

Fiber is a nondigestible or absorbed carbohydrate, so it adds bulk to meals and takes space in your belly causing you to fill full faster and longer without ingesting carbs that youre absorbing.

The anthocyanins found in cabbage help with more than inflammation. Research suggests they add to the health benefits of cabbage by reducing your risk of heart disease. Scientists have found 36 different kinds of anthocyanins in cabbage, which could make it an excellent option for cardiovascular health.

Potassium is a mineral and electrolyte that helps your body control blood pressure. One cup of red cabbage can deliver a healthy amount of potassium as much as 6% of your recommended daily value. This could help lower your blood pressure, reducing your risk for heart disease.

Too much bad cholesterol, or LDL cholesterol, can cause heart problems if it builds up in your arteries. Cabbage contains two substances fiber and phytosterols (plant sterols) that compete with cholesterol to be absorbed by your digestive system. They wind up reducing your bad cholesterol levels and improving your health.

Vitamin K is essential to your well-being. Without it, youd be at risk of developing bone conditions like osteoporosis, and your blood wouldnt be able to clot properly. Enter cabbage, a great source of vitamin K. One cup provides 85% of the recommended daily value.

Vitamin K helps keep our bones strong and our blood clotting well, says Zumpano. Cabbage can give you that boost you need to make sure your levels are adequate, and your body stays protected against illness and disease. And you dont even need to eat that much cabbage to get great health benefits.

Early animal studies suggest that leafy green vegetables like cabbage have phytochemicals that may help protect against cancer. They contain antioxidants and plant compounds like glucosinolates. These sulfur-containing chemicals break down during the digestive process into substances that may help fight cancer cells and clear them from your body.

Excited to add more cabbage to your diet? Just be careful not to go overboard. To maximize its health benefits, increase your cabbage intake slowly and allow your body to adjust. Also, stay hydrated to reduce constipation, which can cause excess gas.

Cabbage might not be the best choice for a romantic night out since eating too much can cause diarrhea, flatulence or abdominal discomfort. It also contains substances that can interfere with medications like blood thinners or cause hypothyroidism, a condition where your thyroid doesnt create enough thyroid hormone and causes your metabolism to slow down.

In most cases, you can avoid side effects by eating cabbage as part of a healthy diet. Talk to your healthcare provider if you experience symptoms or have any concerns.

Cabbage belongs to the Brassica oleracea species of vegetable, along with broccoli, cauliflower, kale and Brussels sprouts. The most common type is green cabbage. But hundreds of other varieties exist in red, white and purple hues, with a range of textures and sizes.

Some forms of cabbage have subtle, delicate flavors, while others pack a peppery punch. Nutrition from cabbage comes from types like:

Cabbage is a versatile vegetable thats affordable, widely available and easy to prepare. Keep it whole and unwashed in the refrigerator until youre ready to eat it, recommends Zumpano. And when youre ready, it wont take long to find easy cabbage recipes that add a (healthy) zing to your diet and color to your plate.

Link:
8 Health Benefits of Cabbage - Health Essentials

Read More...

VICTOR DAVIS HANSON: The mysteries of Long COVID – Las Vegas Review-Journal

Sunday, September 4th, 2022

When the original strain of COVID-19 arrived in spring 2020, a pandemic soon swept the country. Most survived. But hundreds of thousands did not. American deaths now number well more than 1 million.

Amid the tragedy, there initially was some hope that the pernicious effects of the disease would all disappear upon recovery among the nearly 99 percent who survived the initial infection.

Vaccinations by late 2020 were promised to end the pandemic for good. But they did not. New mutant strains, while more infectious, were said to be less lethal, thus supposedly resulting in spreading natural immunity while causing fewer deaths from infection.

But that too was not quite so.

Instead, sometimes the original symptoms, sometimes frightening new ones, not only lingered after the acute phase, but were of increased morbidity.

Now 2 years after the onset of the pandemic, there may be more than 20 million Americans who are still suffering from what is currently known as long COVID a less acute version but one ultimately as debilitating. Some pessimistic analyses suggest well more than 4 million once-active Americans are now disabled from this often-ignored pandemic and out of the workforce.

Perhaps 10 percent to 30 percent of those originally infected with COVID-19 have some lingering symptoms six months to a year after the initial infection. And they are quite physically sick, desperate to get well and certainly not crazy.

So far, no government Marshall plan exists to cure long COVID.

While we know the nature of the virus well by now, no one fathoms what causes long COVIDs overwhelming fatigue, flu-like symptoms, neuralgic impairment, cardiac and pulmonary damage and an array of eerie problems from extended loss of taste and smell to vertigo, neuropathy and brain fog.

Post-viral fatigue has long been known to doctors. Many who get the flu or other viruses such as mononucleosis sometimes take weeks or even months to recover after the initial acute symptoms retire. But no one knows why long COVID often seems to last far longer and with more disability.

Is its persistence due to one theory that SARS-CoV-2 is a uniquely insidious, engineered virus? Or do vaccines and antivirals only help to curb infection, while possibly encouraging more unpredictable mutations?

Who gets long COVID, and why and how is, to paraphrase Winston Churchill, a riddle, wrapped in a mystery, inside an enigma. Those who nearly die from acute COVID-19 can descend into long COVID. But then again so can those with minimal or few initial acute symptoms.

The obese with comorbidities are prone to long COVID, but triathletes and marathon runners are, too. The elderly, the mature, the middle-aged, adolescents and children can all get long COVID. Those with down-regulated and impaired immune systems fight long COVID. But then again so do those with up-regulated and prior robust immunity, as well as people with severe allergies.

Since early 2020, no one has deciphered the cause, although numerous Nobel prizes await anyone who unlocks its mysteries.

Does a weakened but not vanquished SARS-CoV-2 virus hide out and linger, causing an unending immune response that sickens patients? Or does COVID-19 so weaken some long-haulers to the degree that old viruses, long in remission, suddenly flare up again, sickening the host with an unending case, of say, mononucleosis?

Or is the problem autoimmunity?

Is there something unique to the nature of COVID-19 that damages the vital on-and-off buttons of the immune system, causing the body to become stuck in overdrive, as it needlessly sends out its own poisons against itself?

Without knowledge of what explains long COVID, it is hard for researchers to find a cure. After all, is the answer to slow down the immune system to dampen the immune storm or to enhance it to root out lingering viruses?

Do more vaccines help or worsen long COVID? Is the solution some new drug or discovering off-label uses of old medicines? Can a good diet, moderate exercise and patience finally wear out long COVID? Or is its course too unpredictable or near permanent and chronic?

Is long COVID a single phenomenon or a cluster of maladies, each manifesting according to ones own genetic makeup, particular history of past illness, and unique reaction to the initial infection?

If we have few answers, we do have an idea about the costs.

Long COVID may be one of many reasons why in a recession, labor paradoxically still remains scarce. Millions likely stay home in utter disbelief that they are still battling long COVID. Others isolate in deadly fear of getting either the acute or chronic form of the illness.

The social costs to America of this hidden pandemic in lost wages and productivity, family and work disruption and expensive medical care are unknown. But they are likely enormous, still growing and mostly ignored.

Victor Davis Hanson is a distinguished fellow of the Center for American Greatness and a classicist and historian at Stanfords Hoover Institution. Contact at authorvdh@gmail.com.

Read more:
VICTOR DAVIS HANSON: The mysteries of Long COVID - Las Vegas Review-Journal

Read More...

Identification of cervical squamous cell carcinoma feature genes and construction of a prognostic model based on immune-related features – BMC Women’s…

Sunday, September 4th, 2022

Construction of CSCC gene co-expression network and screening of immune-related module

Firstly, the unqualified samples and genes in the TCGA-CESC dataset were removed based on hierarchical clustering, and 253 samples and 4,553 genes were reserved for WGCNA to build the gene co-expression network. =3 (scale-free R2=0.92) was selected as an optimal soft threshold to construct a scale-free network, and finally 15 gene modules were obtained (Table 1). Then, the correlation between the feature genes of each module and four immune-related features (Stromal, Immune, Estimate Scores, and Tumor Purity) was calculated. It was found that brown module was significantly associated with immune status, presenting Immune Score (r=0.88, P=1e-84), Stromal Score (r=0.46, P=1e-14), ESTIMATE Score (r=0.79, P=2e-55) and Tumor Purity (r=-0.82, P=1e-63) (Fig.1). Therefore, the brown module was included in the subsequent study.

The immune-related modules based on WGCNA

Enrichment analysis was performed on 330 genes in the brown module to reveal relevant biological function. The results showed that the genes were largely enriched in the functions and pathways related to immune signal activation and immunomodulation, such as response to interferon-gamma, positive regulation of immune response, adaptive immune response, regulation of cytokine production, myeloid leukocyte activation, regulation of response to biotic stimulus, T cell activation, inflammatory response, negative regulation of immune system process, Type II interferon signaling (IFNG), Lysosome, response to tumor necrosis factor, regulation of viral process, etc. (Fig.2AC).

Enrichment analysis of genes in the brown module. A P value distribution of the top 20 enriched pathways and biological processes in the brown module; B The P value clustering network of genes in the brown module, with the redder the node color is, the more significant P value is; C Network analysis of enriched terms of genes in the brown module. Different node colors indicate different functional or pathway clusters that nodes belong to

The brown module was known to be highly correlated with cellular immunity. In the present study, consensus clustering was conducted on tumor samples based on the expression patterns of genes in the brown module to identify different immune subtypes. Since the grouping was suboptimal when using K=3 as the clustering value, we selected K=3 to divide the samples into three groups (Fig.3AC). The samples obtained were named as cluster A (38 cases), cluster B (132 cases) and cluster C (84 cases). To better understand the immune patterns of the three subgroups, we explored the expression of genes in the brown module in the three subgroups (Fig.3D). The results showed that most of the genes in the brown module were down-regulated in the cluster B subgroup, while most of the genes were up-regulated in the other two subgroups, and the overall level of gene up-regulation in the cluster A subgroup was more evident than that in the cluster C subgroup. Therefore, we assumed that the three subgroups might represent different immune patterns, which was further verified by subsequent analysis.

Consensus clustering analysis of gene expression pattern in the brown module. A Cumulative distribution function (CDF) of consensus clustering when K=2~9; B Relative change of AUC of CDF curve when K=2~9; C Tracking plot results of consensus clustering when K=3; D Heat map of gene expression in different subtypes in the brown module

GSVA was done to explore the biological behaviors of the three tumor immune subtypes. Cluster A enriched in the pathways associated with immune deficiency and disease development, such as PRIMARY IMMUNODEFICIENCY, TYPE I DIABETES MELLITUS, INTESTINAL IMMUNE NETWORK FOR IGA PRODUCTION, ALLOGRAFT REJECTION, etc. Cluster B was enriched in pathways related to immunosuppressive biological processes. Cluster C was mainly enriched in pathways associated with cell adhesion, cytokine and cytotoxic activation pathways, including CYTOSOLIC DNA SENSING PATHWAY, CELL ADHESION MOLECULES CAMS, HEMATOPOIETIC CELL LINEAGE, CYTOKINE NATURAL KILLER CELL MEDIATED CYTOTOXICITY, CYTOKINE RECEPTOR INTERACTION, etc. (Fig.4). These results indicated that the three subtypes have different enrichments in biological pathways, and it was speculated that these subtypes may have different biological behaviors.

Heat maps of GSVA among different subtypes. Red: up-regulated pathways; green: down-regulated pathways

The analysis of cell infiltration in TME showed that there were differences in the contents of B cells, T cells, NK cells, monocytes and macrophages among the three subtypes (Fig.5A). ssGSEA results showed significant differences in CD8 T cells, CD4 T cells, Treg cells, macrophage MD, M1 and dendritic cell contents among the three subtypes (Fig.5B). To further verify the classification, ESTIMATE was used to calculate Stromal Score, ESTIMATE Score, Immune Score, and Tumor Purity based on mRNA data. These indicators were used to distinguish the high, low and medium immune groups. Compared with low immune cell infiltration group, the high immune cell infiltration group had lower Tumor Purity and higher Stromal Score, Immune Score and ESTIMATE Score. Therefore, Cluster A was defined as high immune group, Cluster B as low immune group, and Cluster C as medium immune group (Fig.5C). High immune group was significantly positively correlated with ESTIMATE Score, Immune Score and Stromal Score, but negatively correlated with Tumor Purity (Fig.5D). human leukocyte antigen (HLA) is an expression product of human major compatibility complex and is also a highly polymorphic allogeneic antigen [23]. In the present study, the correlation between immune cell infiltration and HLA family proteins in different subgroups was analyzed to verify the rationality of typing. The results demonstrated that the expression of HLA family gene was significantly downregulated in high immune group compared with in low immune group (Fig.5E). The above results indicated that there were differences in the immune cell infiltration, immune-related scores and HLA family protein expression among subtypes, which also provided support for the rationality of the typing.

Analysis of immune cell infiltration and immune-related indices in different tumor subtypes. A CIBERSORT analysis of differences in immune cell composition among different subtypes; B Differences in the abundance of each immune infiltrating cell among different subtypes; C Heat map of immune cell typing; D Violin plot of the differential analysis of Tumor Purity, ESTIMATE Score, Immune Score and Stromal Score among the three subtypes; E Differences in the expression of HLA family gene among different subtypes

Subsequently, a prognostic model was constructed based on the genes in the brown module. In the TCGA-CESC dataset, the samples with survival time less than 30days were excluded. Then, for the 330 genes in the brown module, a univariate regression analysis was conducted, and 46 genes significantly associated with prognosis were obtained with P<0.01 as the screening condition (Additional file 1: Table S1). Next, lasso and multivariate regression analyses were done on these 46 genes, and 8 feature genes were obtained finally, including ISCU, MSMO1, GCH1, EEFSEC, SPP1, RHOG, LSP1 and TCN2 (Fig.6A, Additional file 2: Table S2). HRs of MSMO1 and SPP1 were higher than 1, which were risk factors for CSCC prognosis, while HRs of ISCU, GCH1, EEFSEC, RHOG, LSP1 and TCN2 were lower than 1, which could be protective factors for CSCC prognosis. The risk scores were calculated based on these 8 feature genes, and the samples were classified into high-risk and low-risk groups. According to the heat map, the expression levels of GCH1, EEFSEC, SPP1, RHOG, LSP1 and TCN2 were decreased overall with the increase of risk score (Fig.6B). Based on the risk score distribution and survival time of the high/low-risk group samples, we found that the number of patients dying increased and the survival time decreased with the increase of risk score (Fig.6CD). Survival curves of the high/low-risk groups also demonstrated that patients in the low-risk group had a higher survival rate (Fig.6E). ROC curve demonstrated the reliability of the risk assessment model in predicting 1-, 3- and 5- year survival rates of samples, with AUC values of 0.8, 0.77 and 0.75 respectively (Fig.6F). Also, the expression statuses of the 8 genes were examined using qRT-PCR, whose results showed that ISCU was downregulated, while MSMO1, GCH1, EEFSEC were upregulated in the tumor tissues (Fig.6G). In addition, this study assessed the correlation between the prognostic model and immune cell infiltration. As a result, the risk score was significantly negatively correlated with 6 immune cells, including B_ cell, CD8_ T cell, CD4_ T cell, neutrophil, dendritic cell and macrophage (Fig.7AF). To verify whether the risk score could be considered as an independent prognostic indicator, univariate and multivariate Cox regressions were introduced based on risk score and clinical features of the samples. As observed in Fig.7GH, risk score could independently serve as prognostic factor. In conclusion, we constructed an 8-feature gene risk assessment model to predict the prognosis of patients with CSCC and proved the favorable predictive ability of this model and revealed the association between the model and cellular immunity.

Construction and assessment of a prognostic model for CSCC. A Forest map of the 8-prognostic feature genes, *P<0.05; B Heatmap of expression of the 8 prognostic feature genes in the high- and low-risk groups; C Risk score distribution of CSCC patients, with green representing the low-risk group and red representing the high-risk group; D Scatter plot of survival status of CSCC patients, with green and red dots representing survival and death, respectively; E KaplanMeier survival curve of the high- and low-risk groups; F ROC curves of the prognostic model predicting 1-, 3-, and 5-year overall survival of patients.; G qRT-PCR was used to measure the mRNA expressions of the feature genes

Correlation between risk score and infiltration degree of 6 immune cells. A Correlation between risk score and B_cell infiltration; B Correlation between risk score and CD4 T cell infiltration; C Correlation between risk score and CD8 T cell infiltration; D Correlation between risk score and dendritic cell infiltration; E Correlation between risk score and macrophage infiltration; F Correlation between risk score and neutrophil infiltration. GH Univariate and multivariate Cox regression for risk score and the clinical features

Original post:
Identification of cervical squamous cell carcinoma feature genes and construction of a prognostic model based on immune-related features - BMC Women's...

Read More...

Is This Popular Montana City The Most Depressed In The Nation? – XL Country

Sunday, September 4th, 2022

In recent years the subject of mental health has come to the forefront. In fact, it seems that every time you turn on any sort of national news, one of the top stories has some sort of connection to mental health.

Experts have said that we're in the middle of a mental health crisis and there are many claims that we don't have sufficient funds or resources to help all of those that are suffering. Of course, here in Montana, we're certainly not immune to the issue; in fact, Montana ranks first when it comes to suicide.

According to new data, we now know that one Montana city is the most depressed in the United States.

Billings ranks number one among U.S. cities, with the highestrate of depression. The data was published by CEUfastand was gathered from the CDC. Billings has a metro area of just over 180 thousand and according to the report, almost one-third (31 percent) of those people have been diagnosed with depression by a professional.

Billings wasn't the only city in the northwest part of the country that made the Top 10. The Spokane Valley area ranked 6th with over 27 percent of the population diagnosed with depression, and Salem, Oregon was in 8th place with almost 26 percent of the population diagnosed with depression.

According to the National Institute of Mental Health, there are many different signs of depression. Below, we have a list of some symptoms:

If you feel like you're depressed, or have any of the symptoms above, remember that there are folks who want and are willing to help you and you're not alone. Organizations like Resources To Recover are a great place to start if you're looking for help, plus you can always call the National Suicide Prevention Line at 1-800-273-8255.

.

KEEP READING: See 25 natural ways to boost your immune system

Goosebumps and other bodily reactions, explained

Read the original:
Is This Popular Montana City The Most Depressed In The Nation? - XL Country

Read More...

First adapted COVID-19 booster vaccines recommended for approval in the EU | European Medicines Agency – European Medicines Agency |

Sunday, September 4th, 2022

The adapted COVID-19 vaccines Comirnaty Original/Omicron BA.1 and Spikevax bivalent Original/Omicron BA.1 are now authorised across the EU. This follows a decision from the European Commission issued on 1 September 2022.

EMAs human medicines committee (CHMP) has recommended authorising two vaccines adapted to provide broader protection against COVID-19. Comirnaty Original/Omicron BA.1 and Spikevax bivalent Original/Omicron BA.1 are for use in people aged 12 years and above who have received at least primary vaccination against COVID-19. These vaccines are adapted versions of the original vaccines Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) to target the Omicron BA.1 subvariant in addition to the original strain of SARS-CoV-2.

Vaccines are adapted (i.e., updated) to better match the circulating variants of SARS-CoV-2. Adapted vaccines can broaden protection against different variants and are therefore expected to help maintain optimal protection against COVID-19 as the virus evolves.

Studies showed that Comirnaty Original/Omicron BA.1 and Spikevax bivalent Original/Omicron BA.1 can trigger strong immune responses against Omicron BA.1 and the original SARS-CoV-2 strain in people previously vaccinated. In particular, they were more effective at triggering immune responses against the BA.1 subvariant than the original vaccines.

Side effects observed with the adapted vaccines were comparable to those seen with the original ones and were typically mild and short-lived.

The two CHMP opinions will now be sent to the European Commission, which will adopt a final decision.

As the pandemic evolves, the EUs strategy is to have a broad range of adapted vaccines that target different SARS-CoV-2 variants so Member States have a plurality of options to meet their needs when they design their vaccination strategies. This is a key element in the overall strategy to combat the pandemic as it is not possible to predict how the virus will evolve in the future and which variants will be circulating this winter. Other adapted vaccines incorporating different variants, such as the Omicron subvariants BA.4 and BA.5, are currently under review by EMA or will be submitted soon, and, if authorised, will further extend the arsenal of available vaccines. The clinical data generated with the original/BA.1 bivalent vaccines recommended today will support the evaluation and authorisation of further adapted vaccines.

The original vaccines, Comirnaty and Spikevax, are still effective at preventing severe disease, hospitalisation and death associated with COVID-19 and will continue to be used within vaccination campaigns in the EU, in particular for primary vaccinations.

National authorities in the EU Member States will determine who should receive which vaccines and when, taking into account factors such as infection and hospitalisation rates, the risk to vulnerable populations, vaccination coverage and vaccine availability.

Comirnaty Original/Omicron BA.1 can be used in people aged 12 years and older, at least 3 months after the last dose of a COVID-19 vaccine.

The CHMPs opinion on Comirnaty Original/Omicron BA.1 is based on 2 studies. One study in adults over 55 years old who had previously received 3 doses of Comirnaty (primary vaccination and a booster) found that the immune response to the Omicron BA.1 subvariant was higher after a second booster dose of Comirnaty Original/Omicron BA.1 than after a second dose of the original Comirnaty vaccine (as measured by the level of antibodies against Omicron BA.1). In addition, the immune response to the original SARS-CoV-2 strain was comparable for both vaccines. The study involved more than 1,800 people, of whom about 300 received Comirnaty Original/Omicron BA.1 in its final composition.

Further data from a study involving over 600 people aged between 18 and 55 years who had previously received 3 doses of Comirnaty showed that the immune response to Omicron BA.1 was higher in people who received a booster with a vaccine containing only the Omicron BA.1 component than in those given a booster with the original Comirnaty vaccine.

Based on these data, it was concluded that the immune response to Omicron BA.1 following a booster with Comirnaty Original/Omicron BA.1 in people aged 18 to 55 years would be at least equal to that in people aged over 55. Further, based on previous data in younger people, it was also concluded thatthe immune response to a booster dose with Comirnaty Original/Omicron BA.1 in adolescents would be at least equal to that in adults.

Spikevax bivalent Original/Omicron BA.1 can be used in adults and adolescents from the age of 12 years, at least 3 months after primary vaccination or a booster dose with a COVID-19 vaccine.

The CHMPs opinion on Spikevax bivalent Original/Omicron BA.1 is based on data from a study involving more than 800 adults aged 18 years and above. The study found that a booster dose of Spikevax bivalent Original/Omicron BA.1 induced a stronger immune response against the SARS-CoV-2 strain and the Omicron subvariant BA.1 compared with a booster dose of the original Spikevax vaccine. The study compared the level of antibodies in people previously vaccinated with a primary series and booster dose of Spikevax, and who were given a second booster dose of either Spikevax or Spikevax bivalent Original/Omicron BA.1. It was also concluded that Spikevax bivalent Original/Omicron BA.1 could be used as a first booster after primary vaccination and that the immune response induced by a booster dose of Spikevax bivalent Original/Omicron BA.1 in adolescents aged 12-17 years would be at least equal to that in adults, given that previous data with Spikevax have shown a comparable effect.

The adapted vaccines work in the same way as the original vaccines.

Both adapted vaccines work by preparing the body to defend itself against COVID-19. Each vaccine contains molecules called mRNA which have instructions for making the spike proteins of the original SARS-CoV-2 and the Omicron subvariant BA.1. The spike protein is a protein on the surface of the virus which the virus needs to enter the bodys cells and can differ between variants of the virus. By adapting vaccines, the aim is to broaden protection against different variants.

When a person is given one of these vaccines, some of their cells will read the mRNA instructions and temporarily produce the spike proteins. The persons immune system will then recognise those proteins as foreign and activate natural defences antibodies and T cells against them.

If, later on, the vaccinated person comes into contact with the virus, the immune system will recognise the spike protein on its surface and be prepared to attack it. The antibodies and immune cells can protect against COVID-19 by working together to kill the virus, preventing its entry into the bodys cells and destroying infected cells.

The mRNA molecules from the vaccines do not stay in the body but are broken down shortly after vaccination.

The companies marketing Spikevax and Comirnaty submitted applications (called variation applications) to change the current marketing authorisations of the authorised vaccines Comirnaty and Spikevax and include the use of adapted vaccines. These applications included data on the quality and safety of the adapted vaccines, and their ability to trigger immune responses against various strains of SARS-CoV-2.The review was carried out by EMAs Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use. The CHMP opinion has been forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States.

Read the original:
First adapted COVID-19 booster vaccines recommended for approval in the EU | European Medicines Agency - European Medicines Agency |

Read More...

Potential of Vaccines in Treating Parkinson’s, Alzheimer’s Detailed | AC Immune to Launch Trial of Vaccine in Early-stage Parkinson’s – Parkinson’s…

Sunday, September 4th, 2022

In a webinar hosted by AC Immune, scientists discussed the various advantages of vaccines ranging from their expected safety and long-lasting immune responses to potentially lower costs in treating and possibly preventingParkinsonsand Alzheimers disease.

The Key Opinion Leader webinar, broadcasted on Aug. 24 and available for viewing, offered a presentation by Cynthia A. Lemere, PhD, a scientist at the Ann Romney Center for Neurologic Diseases at Brigham & Womens Hospital and an associate professor of neurology at the Harvard Medical School. Lemere also works as a scientific advisor and consultant for AC Immune, among other companies.

Vaccines are a form of active immunotherapy for neurodegenerative diseases, which work bystimulating the immune system to produce antibodies against the abnormal, or misfolded, proteins driving these diseases. In the case of Parkinsons, clumps of the misfolded alpha-synuclein proteinspread throughout the brain and contribute to nerve cell death and disease progression.

AC Immune is planning to open a Phase 2 clinical trial of ACI-7104, a potential vaccine against the toxic alpha-synuclein protein in Parkinsons patients this year.

A newer generation of vaccines, called multi-epitope vaccines, target several epitopes the part of a protein that elicits an immune response on misfolded proteins. As such, they are designed to elicit a more powerful immune response, AC Immune reported in an accompanying company press release. Multi-epitope vaccines also contain adjuvants, additional components that boost immune responses.

Vaccines are designed to provide long-lasting immune activation, the speakers stated, leading to a consistent and gradual production of antibodies against misfolded protein clumps. This allows for greater safety and long-term efficacy than is possible with synthetic or lab-made monoclonal antibodies that only target one epitope. Monoclonal antibody treatment, the scientists explained, is a passive immunotherapy, with a relatively short-lived peak in antibody production compared with vaccines.

Its really a question of balancing efficacy and safety, Lemere said, speaking of monoclonal antibodies in studies for Alzheimers disease relative to potential vaccines.

Vaccines also enhance a persons own immune response.Active vaccination is a way to have the body basically make antibodies,Lemere said.

Vaccines can be administered as a simple injection, she added, while monoclonal antibodies are often infused over four hours during regularly scheduled hospital or clinic visits. They also can be cost-saving and less of a burden to patients, needing to be given possibly only once or twice a year, she added.

Contrary to monoclonal antibodies, however,the immune response triggered by vaccines cannot be shut down.

The ability of vaccines to safely and specifically target multiple epitopes on the toxic drivers of neurodegenerative disease makes them uniquely suited to address the unmet needs of patients, Lemere said in the release. Data from prior clinical studies conducted by AC Immune and others clearly highlight the therapeutic potential of vaccines and provide a strong scientific rationale for the Companys ongoing and planned trials.

Marie Kosco-Vilbois, PhD, chief scientific officer at AC Immune, and Johannes Streffer, MD, the companys chief medical officer, also spoke at the event.Theypresented an overview of the companys goals and pipeline ofcandidate vaccines.

ACI-7104, its lead candidate for Parkinsons and other synucleinopathies, diseases characterized by the accumulation of misfolded alpha-synuclein aggregates, was initially developed by Affiris and later acquired by AC Immune. It is designed to trigger a specific immune response against toxic aggregates of alpha-synuclein.

A Phase 1 clinical trial (NCT01568099) and its extension studies, sponsored by Affiris, in 21 people with early-stage Parkinsons supported the vaccines safety and tolerability with repeat injections (six doses in total). Patients treated at the highest dose, 75 micrograms, also showed a 51% drop inlevels of alpha-synuclein aggregates in the cerebrospinal fluid that surrounds the brain and spinal cord, its researchers reported in 2020, supporting further clinical testing.

The planned Phase 2 trial of ACI-7104 will evaluate an improved version of the vaccine, Streffer said. It is to be an adaptive and biomarker-based study that will initially determine an optimally safe and effective dose and confirm the Phase 1 trials findings. Up to 150 additional Parkinsons patients will then be enrolled for treatment and assessment at the selected dose.

This study is in preparation, Streffer said. We are planning to include the first participants later this year.

AC Immune also has two candidate vaccines for Alzheimers disease, ACI-35.030 and ACI-24.060, in clinical testing.

We believe these programs, together with our cutting-edge diagnostic imaging agents, position AC Immune to lead the field towards the earlier diagnosis and prevention of neurodegenerative disease, said Andrea Pfeifer, CEO ofAC Immune.

Originally posted here:
Potential of Vaccines in Treating Parkinson's, Alzheimer's Detailed | AC Immune to Launch Trial of Vaccine in Early-stage Parkinson's - Parkinson's...

Read More...

What Are Zombie Cells? Here’s How They Impact Aging – Prevention Magazine

Sunday, September 4th, 2022

Its a fact of life: If youre lucky enough, you will get older and, with that, your body will show signs of aging. Research has been ongoing to try to determine what, exactly, is behind this process and scientists have largely linked the aging process with one biological factor: Senescent cells, aka zombie cells.

A recent study published in Nature Structural & Molecular Biology specifically links zombie cells to age-related diseases like cancer, dementia, and heart disease, and breaks down how these cells develop.

The study found the oxidative damage (damage that happens as a result of an imbalance between free radicals and antioxidants in your body) to telomeres, the protective ends of chromosomes, can spark the formation of zombie cells.

This isnt the only research on zombie cells: Scientists have been analyzing these cells and their role in aging for years.

If youve never heard of zombie cells before, fair. But, of course, you probably have someor a lot ofquestions about what these are and what role they play in aging. Heres a breakdown.

Its important to quickly recap how cells in your body work. There is a process called mitosis, which is a fundamental process for life, where a cell duplicates all of its contents and splits to form two identical cells, Medline Plus explains. When mitosis isnt regulated correctly, you can develop health problems like cancer.

Zombie cells, aka senescent cells, are cells that stop dividing, according to the National Institutes of Health (NIH). When youre younger, your immune system spots these cells and eliminates them from your body, Sabrina Barata, M.D., a primary care doctor at Mercy Personal Physicians, explains. But, as you get older, your immune system doesnt have as large of a capacity to do this.

Zombie cells simply stick around in your body. They dont diethey become resistant to death, says researcher Paul Robbins, Ph.D., associate director of the Institute on the Biology of Aging and Metabolism and the Medical Discovery Team on the Biology of Aging at the University of Minnesota. They stay in your body forever.

These cells release certain molecules that can spark inflammation and even harm other cells, Dr. Robbins says. Theyve also been linked to the growth of cancerous cells, per the NIH.

However, Dr. Robbins says, senescence is seen as an anti-cancer mechanism because it stops cells that may have become abnormal from continuing to replicate.

I would hypothesize that yes, everyone has these cells, Dr. Robbins says. Your burden of cells increases with age and older people or people with chronic diseases may have more.

Cells stop dividing after theyve divided so many times or acquire so many mutations that theyre at risk of becoming abnormal or potentially making you sick, the NIH says.

Zombie cells become more common as people age. Your immune system gets rid of these cells when youre young but, when you get older, it cant clear them as effectively, Dr. Robbins says. Research has found that tinkering with these cells can help extend lifein mice, at least.

Landmark research from Jan van Deursen, Ph.D., of the Mayo Clinic actually removed zombie cells from living mice. Van Deursen and his team discovered that injecting a certain drug triggered the death of these zombie cells.

In follow-up research, the team found that treating mice to remove zombie cells extended their median lifespans by 17% to 42%, depending on the mices sex, diet, and genetic background. The mice that were treated also usually looked healthier than those that werent treated and were more likely to have spontaneous activity and explore thingssigns of youth.

Thats what doctors think right now. If we understand why senescent cells happen and how to reverse them, we have the ability to have healthier aging with less debility, says Santosh Kesari, M.D., Ph.D., a neurologist at Providence Saint Johns Health Center in Santa Monica, Calif., and regional medical director for the Research Clinical Institute of Providence Southern Calif.

Dr. Robbins points out that zombie cells are interconnected with other things that go wrong as we age. Those include things like dysfunction in your stem cells, changes in metabolism, and dysfunction of your mitochondria, which generate energy to power your cells, he says.

If one of these things are affected, the others are, too, Dr. Robbins says. Theyre all linked. Meaning, if you can target and wipe out zombie cells, your metabolism and energy may improve, he says.

Dr. Barata says that studying these cells can absolutely help lead to advances in healthy aging. If we can find a way to kill off these cells, they wont accumulate in the body, she says. That will protect us from diseases like dementia, certain cancers, and cardiovascular disease.

Currently, research is ongoing to study the impact of targeting zombie cells and certain diseases like Alzheimers disease, osteoarthritis, and diabetes. We will know their impact quicklywithin in a few years, Dr. Robbins says

Korin Miller is a freelance writer specializing in general wellness, sexual health and relationships, and lifestyle trends, with work appearing in Mens Health, Womens Health, Self, Glamour, and more. She has a masters degree from American University, lives by the beach, and hopes to own a teacup pig and taco truck one day.

See original here:
What Are Zombie Cells? Here's How They Impact Aging - Prevention Magazine

Read More...

What To Know About Hand, Foot and Mouth Disease – Health Essentials

Sunday, September 4th, 2022

Your child is cranky, running a fever and going through tissues like theres no tomorrow.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services.Policy

Then, they wont eat.

Then, you see a rash. And their best friends mom from daycare calls and says her child hasnt been feeling well either.

And now its all making sense.

It might be hand, foot and mouth disease, a common but highly contagious childhood illness that makes its way very quickly through households, daycares and schools.

Like most viruses, hand, foot and mouth is fairly contagious, says pediatrician Dana Schmidt, MD. So, in a daycare or school setting, it can spread very quickly.

Caused by a strain of the coxsackievirus, hand, foot and mouth disease is best known for the blister-like rash that appears on the you guessed it hands, feet and mouth. Contrary to its name, though, the rash can appear all over the body.

Dr. Schmidt answers your most pressing questions about this common and highly contagious illness.

A: Hand, foot and mouth disease will initially look similar to a cold. After a few days, a rash will start to form.

The first symptoms of hand, foot and mouth disease are similar to a cold and include:

Its during this first phase of the disease that youre most contagious and most likely to pass the virus to other people, Dr. Schmidt says.

After the initial symptoms set in, you may notice small sores inside of your mouth, including on your gums, tongue and roof of your mouth. The spots may appear like small red bumps or larger open sores.

These sores can make swallowing painful, so its common for people with hand, foot and mouth disease to not want to eat. Its also common that mouth sores will cause children to drool.

Sometimes, the rash stops at the mouth. Thats called herpangina (and the advice below still applies).

In the next day, you may notice sores spread to the hands and feet, and possibly elsewhere.

The hallmarks of the virus are a rash that appears on the hands, feet and mouth, but the rash can often be found all over the body, including the trunk and genitals, Dr. Schmidt states.

The look of the rash can vary from person to person. Some people experience small, red spots that dont cause any discomfort. Others may have larger spots, sometimes filled with pus, that may be painful. The spots may contain the virus, so avoid touching the rash as much as possible, and wash your hands thoroughly after coming in contact with blisters. The rash usually isnt itchy.

The spots should clear up in about 10 days.

A: Youre most contagious with hand, foot and mouth disease during the first few days of being sick often before blisters appear. Once the blisters dry up, youre less likely to pass on the virus, though it can live in your stool for weeks after the rash clears.

Hand, foot and mouth disease can be spread in several ways:

If your child becomes infected, prevent the spread by keeping them home from daycare, school or other group activities. If youre infected, stay home from work or school.

A: Yes. Hand, foot and mouth disease is very common and usually affects infants and children under the age of 5. But because its so infectious, it can spread among family members and daycare providers. It can make older kids, teenagers and adults sick.

A: Yes. Dr. Schmidt explains that because multiple viruses can cause hand, foot and mouth disease, its possible to catch the virus multiple times.

You can do several things to prevent or reduce the spread of hand, foot and mouth disease:

Hand, foot and mouth disease has no specific treatment, although the Centers for Disease Control and Prevention (CDC) reports that most people get better on their own within seven to 10 days. But you can treat symptoms of the virus with over-the-counter pain medications.

Its also important to stay hydrated. Because mouth sores can make eating and drinking uncomfortable, dehydration is a common side effect. Avoid foods and drinks that are acidic, like orange juice, as they can irritate mouth sores. Stick to milder or cold foods. Older children and adults may also relieve some discomfort with salt water gargles, although this treatment isnt recommended for infants, toddlers or younger children.

Be especially vigilant if hand, foot and mouth disease symptoms become severe, or if you or your child has a weak immune system or becomes dehydrated. Talk with a healthcare provider if the fever doesnt go away after three days or if all symptoms dont improve after 10 days.

Read the original:
What To Know About Hand, Foot and Mouth Disease - Health Essentials

Read More...

On maternity and the stronger immune response in women – Nature.com

Friday, August 19th, 2022

Ecological model

We start with an ecological model of resident host-pathogen dynamics that assumes these populations are, respectively, genetically homogeneous. The ecological model underlies the evolutionary model we develop later. A complete description of the model, and the methods of analysis that follow, can be found in theSupplementary Information.

We consider a population of hosts classified according to their sex and disease status. At time t, there are Si=Si(t) sex-i individuals not infected by the pathogen, but susceptible to future infection (i=f for females, i=m for males). At time t there are also Ii=Ii(t) sex-i individuals who are not only infected with the pathogen but also able to transmit their infection to others. Our specific goal in this section is to develop a mathematical description of how the numbers of hosts in the various classes change over time.

The number of hosts in the population changes as a result of birth events. Following previous work44,45, we model the host mating rate using the harmonic mean of the population sizes of females and males. Assuming a one-to-one birth sex ratio, then newly born hosts of either sex join the population at rate (frac{b({S}_{f}+{I}_{f})({S}_{m}+{I}_{m})}{N}) where b>0, and N=N(t) denotes the total population size at time t. We assume that newborns produced by susceptible mothers are, themselves, susceptible. By contrast, we suppose that newborns produced by infected mothers acquire their mothers infection with probability v, where v is what we have called the vertical transmission rate31. Host number also changes because of death events. Hosts in every class experience natural mortality at per-capita rate N, where is a positive constant. Hosts infected by the pathogen also experience disease-related mortality at per-capita rate i (a measure of pathogen virulence) (Fig.7).

This model incorporates two sexes (females in red and males in blue) and vertical transmission (dashed line). The flow between compartments is represented by arrows and expressions next to each arrow represent the flow rate. Evolving phenotypes and drivers of their evolution are indicated in green and purple, respectively. Source data are provided as a Source Data file.

Numbers of hosts in any particular class changes as their disease-status changes. For example, we allow infected individuals to recover at per-capita rate i (a measure of host immunocompetence). We assume that, upon recovery, hosts move immediately into the appropriate susceptible group. In this way, we ignore the possibility that recovery implies immunity to subsequent infection. The disease status of hosts can also change because of horizontal disease-transmission events. We approach horizontal transmission in a standard way and assume that susceptible sex-i hosts acquire the pathogen horizontally from their infected sex-j counterparts at a total rate of SiijIj. Here, ij is a constant that reflects the transmissibility of the pathogen. We assume that when a host acquires an infection horizontally, it immediately becomes infectious (Fig.7).

The model described above is summarised mathematically using the following system of differential equations:

$$frac{d{S}_{f}}{dt}=frac{b({S}_{f}+(1-v){I}_{f})({S}_{m}+{I}_{m})}{N}+{gamma }_{f}{I}_{f}-{S}_{f}{beta }_{ff}{I}_{f}-{S}_{f}{beta }_{fm}{I}_{m}-mu N{S}_{f}$$

(1a)

$$frac{d{S}_{m}}{dt}=frac{b({S}_{f}+(1-v){I}_{f})({S}_{m}+{I}_{m})}{N}+{gamma }_{m}{I}_{m}-{S}_{m}{beta }_{mf}{I}_{f}-{S}_{m}{beta }_{mm}{I}_{m}-mu N{S}_{m}$$

(1b)

$$frac{d{I}_{f}}{dt}=frac{bv{I}_{f}({S}_{m}+{I}_{m})}{N}+{S}_{f}{beta }_{ff}{I}_{f}+{S}_{f}{beta }_{fm}{I}_{m}-({gamma }_{f}+{alpha }_{f}+mu N){I}_{f}$$

(1c)

$$frac{d{I}_{m}}{dt}=frac{bv{I}_{f}({S}_{m}+{I}_{m})}{N}+{S}_{m}{beta }_{mf}{I}_{f}+{S}_{m}{beta }_{mm}{I}_{m}-({gamma }_{m}+{alpha }_{m}+mu N){I}_{m}.$$

(1d)

Under a reasonable set of conditions, the previous system tends, over time, to an equilibrium state in which infections are endemic.

To study how pathogens disease-induced mortality and the hosts immune system respond to selection, we assume that each faces a life-history trade-off.

First, the pathogens ability to transmit horizontally trades off against the duration of any given infection it establishes. Following the previous authors30,46,47, we capture this trade-off by assuming

$${beta }_{ij}=beta ({alpha }_{j})=frac{{beta }_{max }{alpha }_{j}}{{alpha }_{j}+d}quad ,{{mbox{for}}},,j=f,;m,$$

(2)

where ({beta }_{max },,d , > , 0) are constants. Equation (2) implies that the nature of the trade-off faced by a pathogen is the same in both female and male hosts. Specifically, a pathogen can only increase its rate of horizontal transmission by increasing the disease-induced mortality rate experienced by its host (which, in turn, reduces the duration of infection). Equation (2) also says the horizontal transmission rate saturates at ({beta }_{max }) (independent of host sex), and does so more quickly as the parameter d is reduced (again, independent of host sex). Note also that Equation (2) does not depend on i: the sex of the susceptible host to whom the pathogen is transmitted.

For their part, hosts face a trade-off between investing resources in their immune system and their reproductive success. Increased immune investment is reflected in an increased recovery rate. To capture the hosts trade-off, then, we treat birth rate b as a decreasing function of the recovery rate. Moreover, we assume that the decrease in b is experienced by the host regardless of its disease status. In other words, we assume that cost associated with the immune system is an ongoing one, incurred mainly because of maintenance27 (this assumption model innate immunocompetence best) rather than being due to the activation that follows an infection48 (this assumption would model adaptive immunocompetence best). As noted in the Discussion, we relax this assumption in theSupplemental Material and compare the results for maintenance and activation costs. As an example, here, we point to evidence that shows female sex hormones enhance the immune system but simultaneously reduce the likelihood of conception and increase the chances of spontaneous abortion49,50,51. In mathematical terms, we capture the hosts trade-off using

$$b=b({gamma }_{f},{gamma }_{m})={b}_{max },{e}^{-{c}_{f}{gamma }_{f}^{2}},{e}^{-{c}_{m}{gamma }_{m}^{2}}$$

(3)

where ci reflects the rate at which fertility is reduced as sex-i immune function is increased (cost of recovery above). Equation (3) generalises the birth rate functions used previously27,48 to our sex-specific setting. The fact that b in this equation depends on both f and m reflects the fact that the reduced fertility of one mate affects the fertility of its partner16.

Our approach to modelling the co-evolution of host and pathogen is rooted in the adaptive-dynamics methodology52,53,54. For the pathogen population, we build a fitness expression that measures the success of a rare mutant strain in a population close to the endemic equilibrium established by the system (1) (indicated as ({bar{S}}_{i}), ({bar{I}}_{i}), and (bar{N})). Assuming that the mutant strain of pathogen is associated with a disease-induced mortality rate equal to ({tilde{alpha }}_{i}) in sex-i hosts, the number of mutant infections, ({tilde{I}}_{i}={tilde{I}}_{i}(t)) changes according to

$$frac{d{tilde{I}}_{f}}{dt}=frac{bv{tilde{I}}_{f}({bar{S}}_{m}+{bar{I}}_{m})}{bar{N}}+{bar{S}}_{f}beta ({tilde{alpha }}_{f}){tilde{I}}_{f}+{bar{S}}_{f}beta ({tilde{alpha }}_{m}){tilde{I}}_{m}-({gamma }_{f}+{tilde{alpha }}_{f}+mu bar{N}){tilde{I}}_{f}$$

(4a)

$$frac{d{tilde{I}}_{m}}{dt}=frac{bv{tilde{I}}_{f}({bar{S}}_{m}+{bar{I}}_{m})}{bar{N}}+{bar{S}}_{m}beta ({tilde{alpha }}_{f}){tilde{I}}_{f}+{bar{S}}_{m}beta ({tilde{alpha }}_{m}){tilde{I}}_{m}-({gamma }_{m}+{tilde{alpha }}_{m}+mu bar{N}){tilde{I}}_{m}.$$

(4b)

The system in (4) is linear and its long-term behaviour is determined by a dominant Lyapunov exponent of the mapping. We capture the information provided by the dominant Lyapunov exponent with the pathogen-fitness function, ({W}_{alpha }({tilde{alpha }}_{f},{tilde{alpha }}_{m},{alpha }_{f},{alpha }_{m})) using techniques laid out by the ref. 55 (see alsoSupplemental Information). When this function is greater than 1 the mutant invades and eventually displaces56 the resident strain associated with the i phenotype. When the function ({W}_{alpha }({tilde{alpha }}_{f},{tilde{alpha }}_{m},{alpha }_{f},{alpha }_{m})) is less than 1 the mutant does not invade and is eliminated from the population. With these facts in mind, we say that selection acts to move i in the direction given by the sign of (frac{partial {W}_{alpha }}{partial {tilde{alpha }}_{i}}{left|right.}_{tilde{alpha }=alpha }) where (tilde{alpha }=alpha) is shorthand for ({tilde{alpha }}_{i}={alpha }_{i}) for all i. Specifically, when this partial derivative is positive i is increasing, and when it is negative i is decreasing.

We follow a similar procedure for the host population by introducing, into the equilibrium population, a rare mutant-type host genotype that results in a recovery rate of ({hat{gamma }}_{i}) when expressed by sex-i hosts. We denote the numbers of susceptible and infected sex-i mutant-type hosts as ({hat{S}}_{i}) and ({hat{I}}_{i}), respectively. We assume that hosts are diploid, and so, strictly speaking, the hosts who contribute to ({hat{S}}_{i}) and ({hat{I}}_{i}) categories are heterozygotes (the numbers of homozygote mutants are negligible). While it remains rare, the dynamics of the mutant-host lineage can be described using

$$frac{d{hat{S}}_{f}}{dt}= frac{frac{b({hat{gamma }}_{f},{gamma }_{m})}{2}({hat{S}}_{f}+(1-v){hat{I}}_{f})({bar{S}}_{m}+{bar{I}}_{m})+frac{b({gamma }_{f},{hat{gamma }}_{m})}{2}({bar{S}}_{f}+(1-v){bar{I}}_{f})({hat{S}}_{m}+{hat{I}}_{m})}{bar{N}}\ +{hat{gamma }}_{f}{hat{I}}_{f}-{hat{S}}_{f}{beta }_{ff}{bar{I}}_{f}-{hat{S}}_{f}{beta }_{fm}{bar{I}}_{m}-mu bar{N}{hat{S}}_{f}$$

(5a)

$$frac{d{hat{I}}_{f}}{dt}= frac{frac{b({hat{gamma }}_{f},{gamma }_{m})}{2}v{hat{I}}_{f}({bar{S}}_{m}+{bar{I}}_{m})+frac{b({gamma }_{f},{hat{gamma }}_{m})}{2}v{bar{I}}_{f}({hat{S}}_{m}+{hat{I}}_{m})}{bar{N}}\ +{hat{S}}_{f}{beta }_{ff}{bar{I}}_{f}+{hat{S}}_{f}{beta }_{fm}{bar{I}}_{m}-({hat{gamma }}_{f}+{alpha }_{f}+mu bar{N}){hat{I}}_{f}$$

(5b)

$$frac{d{hat{S}}_{m}}{dt}= frac{frac{b({hat{gamma }}_{f},{gamma }_{m})}{2}({hat{S}}_{f}+(1-v){hat{I}}_{f})({bar{S}}_{m}+{bar{I}}_{m})+frac{b({gamma }_{f},{hat{gamma }}_{m})}{2}({bar{S}}_{f}+(1-v){bar{I}}_{f})({hat{S}}_{m}+{hat{I}}_{m})}{bar{N}}\ +{hat{gamma }}_{m}{hat{I}}_{m}-{hat{S}}_{m}{beta }_{mf}{bar{I}}_{f}-{hat{S}}_{m}{beta }_{mm}{bar{I}}_{m}-mu bar{N}{hat{S}}_{m}$$

(5c)

$$frac{d{hat{I}}_{m}}{dt}= frac{frac{b({hat{gamma }}_{f},{gamma }_{m})}{2}v{hat{I}}_{f}({bar{S}}_{m}+{bar{I}}_{m})+frac{b({gamma }_{f},{hat{gamma }}_{m})}{2}v{bar{I}}_{f}({hat{S}}_{m}+{hat{I}}_{m})}{bar{N}}\ +{hat{S}}_{m}{beta }_{mf}{bar{I}}_{f}+{hat{S}}_{m}{beta }_{mm}{bar{I}}_{m}-({hat{gamma }}_{m}+{alpha }_{m}+mu bar{N}){hat{I}}_{m}.$$

(5d)

The birth terms in the preceding system of equations reflect (a) the fact that the mutant host, while it is rare, mates only homozygous resident hosts and (b) only half of the matings between heterozygous mutants and homozygous residents result in mutant offspring. Since the dynamics described by (5) are linear, we can again measure fitness (this time for the host) using the dominant Lyapunov exponent. We summarise the relevant information contained in this exponent with the host fitness function ({W}_{gamma }({hat{gamma }}_{f},{hat{gamma }}_{m},{gamma }_{f},{gamma }_{m})), again using techniques outlined by ref. 55. In keeping with the description of pathogen evolution, we assert that the hosts i is increasing when (frac{partial {W}_{gamma }}{partial {gamma }_{i}}{left|right.}_{hat{gamma=gamma }}) is positive, and decreasing when this partial derivative is negative, where (hat{gamma }=gamma) is shorthand for ({hat{gamma }}_{i}={gamma }_{i}) for all i.

We want to identify where the action of selection takes the resident pathogen and host traits (i and i, respectively) in the long term. As mentioned above, the model is too complicated to support exact mathematical predictions. Consequently, our methods rely on numerical simulation implemented in Matlab57. All Matlab code is publicly available (see Code Availability).

The numerical simulation takes as its input a set of parameters and an initial estimate of the long-term result of selection on co-evolution of pathogen and host ({alpha }_{i}^{*}), and ({gamma }_{i}^{*}) for i=f, m. The estimate is updated by (i) finding the corresponding equilibrium solution to Equation (1) in a manner that verifies its asymptotic stability, (ii) using that equilibrium solution to estimate partial derivatives (frac{partial {W}_{alpha }}{partial {tilde{alpha }}_{i}}{left|right.}_{tilde{alpha=alpha }}) and (frac{partial {W}_{gamma }}{partial {hat{gamma }}_{i}}{left|right.}_{hat{gamma=gamma }}) for i=f, m, and finally (iii) incrementing or decrementing elements of the estimate following the sign of the appropriate partial derivative. Steps (i)(iii) are repeated until the absolute value of all partial derivatives is within a tolerance of zero. The result of the simulation is an estimate of the convergence stable58,59 co-evolutionary outcome, assuming f and m, and f and m can be adjusted independently. Importantly, this predicted co-evolutionary outcome also corresponds to a system in which the pathogen is established in a stable equilibrium population of hosts.

Finally, we verified numerically that the convergence-stable estimate corresponded to a two-dimensional evolutionarily stable result60 for pathogen and host, respectively. For this reason, we can also refer to predictions generated by our numerical simulation as a continuously stable state, in analogy to the definition established by ref. 61.

Further information on research design is available in theNature Research Reporting Summary linked to this article.

Continued here:
On maternity and the stronger immune response in women - Nature.com

Read More...

New study could change what we eat to supercharge immune system and fight disease – WOODTV.com

Friday, August 19th, 2022

GRAND RAPIDS, Mich. (WOOD) The soldiers of our immune system were long thought to be fueled only by the foods we eat. However, researchers at Van Andel Institute believe the findings from their new study reveal T cells have a much wider appetite than originally thought.

Every process in the body is powered by metabolism, which in turn is fueled by the nutrients we consume through our diet, Russell Jones, Ph.D., chair of Van Andel Institutes Department of Metabolism and Nutritional Programming said. We found that immune cells are much more flexible in selecting the nutrient fuels they consume and, importantly, that they prefer some nutrients that were previously dismissed as waste. This understanding is crucial for optimizing T cell responses and developing new strategies for boosting our ability to fight off disease.

Jones, who is the co-author of the study published this week in Cell Metabolism, says the findings could create a path for personalized dietary recommendations that would supercharge immune cells and provide more effective therapies for cancer and other diseases.

Joneses research took a new approach to studyin T cells. In previous studies, the cells were grown in lab dishes with nutrient-contatining media. But Jones believed those nutrients were similar to a diet of eggs and toast. This time, Jones and his colleagues developed a more diverse sample of nutrients for the research and the outcome was much different.

We found that, when we offer them a full buffet, these cells actually prefer a wider array of fuels than previously believed, Jones said. This has major implications for how we tailor dietary recommendations as ways to promote health and combat disease.

Jones explains the research through what they discovered from lactate, a cellular waste that causes muscle aches and pains and a byproduct of cancer cells that allows the disease to attack other tissue and avoid the immune system. When the T cells were given the choice between glucose and lactate, they chose the lactate to power their energy production which enhanced their overall function.

According to VAI, there is research that suggests too much lactate is bad for T cells, but Jones work provides the idea that small amounts may increase their overall function.

Jones and his team plan to take their findings and use them to take a closer look at the unique connection between metabolism and the immune system to learn more about how they work together.

Hear from Dr. Jones below.

See the original post here:
New study could change what we eat to supercharge immune system and fight disease - WOODTV.com

Read More...

Extending dogs’ lives, and sex and the immune system – MIT Technology Review

Friday, August 19th, 2022

Matt Kaeberlein is what you might call a dog person. He has grown up with dogs and describes his German shepherd, Dobby, as really special. But Dobby is 14 years oldaround 98 in dog years. Im very much seeing the aging process in him, says Kaeberlein, who studies aging at the University of Washington in Seattle.

Kaeberlein is co-director of the Dog Aging Project, an ambitious research effort to track the aging process of tens of thousands of companion dogs across the US. He is one of a handful of scientists on a mission to improve, delay, and possibly reverse that process to help them live longer, healthier lives.

But dogs are just the beginning. Because theyre a great model for humans, anti-aging or lifespan-extending drugs that work for dogs could eventually benefit people, too. In the meantime, attempts to prolong the life of pet dogs can help people get onboard with the idea of life extension in humans. Read the full story.

Jessica Hamzelou

The quest to show that biological sex matters in the immune system

For years, microbiologist Sabra Klein has painstakingly made the case that sexdefined by biological attributes such as our sex chromosomes, sex hormones, and reproductive tissuescan influence immune responses.

Through research in animal models and humans, Klein and others have shown how and why male and female immune systems respond differently to the flu virus, HIV, and certain cancer therapies, and why most women receive greater protection from vaccines but are also more likely to get severe asthma and autoimmune disorders (something that had been known but not attributed specifically to immune differences.)

In the 1990s, scientists often attributed such differences to gender rather than sexto norms, roles, relationships, behaviors, and other sociocultural factors as opposed to biological differences in the immune system. Klein has helped spearhead a shift in immunology, a field that long thought sex differences didnt matterand shes set her sights on pushing the field of sex differences even futher. Read the full story.

View original post here:
Extending dogs' lives, and sex and the immune system - MIT Technology Review

Read More...

Sure Signs Your Immune System Isn’t as Strong as it Should Be Eat This Not That – Eat This, Not That

Friday, August 19th, 2022

Prioritizing your health has never been more important. As COVID cases continue to spike and the monkeypox outbreak has now become a public health emergency, having a strong immune system is essential. Daily habits can impact our immune health and lifestyle choices such as smoking, poor diet, and too much alcohol consumption can weaken your immunity. But there are ways to help strengthen our body and knowing the signs of a troubled immune system is a start. Eat This, Not That! Health spoke with Dr. Tom Yadegar, Pulmonologist and Medical Director of the Intensive Care Unit at Providence Cedars-Sinai Tarzana Medical Center who shares what to know about your immune system and warning signals it's not as healthy as it should be. Read onand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID.

Dr. Yadegar states, "The immune system is the defender of the body. Composed of two arms, innate and adaptive, the innate system is a nonspecific response that fights any type of foreign invader that comes into contact with the body. This arm is generally the same in most people and is composed of white cells. The second arm, known as the adaptive immune system, is specific to the foreign invader and targets it using antibodies from previous infections or vaccines."

"When exposed to a foreign invader, the immune system creates antibodies in response to prevent severe symptoms in case of repeated exposure," says Dr. Yadegar. "When this process turns against healthy tissue instead of foreign pathogens, the immune system attacks the body, leading to an autoimmune state."

Dr. Yadegar shares, "Getting proper sleep, nutrition and regular exercise is a hallmark to keeping the immune system functional. Adequate vitamin intake, including vitamin C and vitamin D, is also important in ensuring a strong immune system. Patients who may have immunodeficiency, such as IgG deficiency, can also receive infusions to help keep their immune system healthy."

Dr. Yadegar tells us, "Fighting infections requires a lot of energy. When the body is depleted of its normal energy level, the immune system is weakened and can become susceptible to opportunistic infections. People generally feel this when they are tired. Ensuring a schedule of restful sleep, eating a balanced diet with fruits and vegetables and drinking enough water helps ensure your immune system is ready to answer the call of an infection."6254a4d1642c605c54bf1cab17d50f1e

According to Dr. Yadegar, "Infections that require multiple courses of antibiotics within a year may be a sign of a weakened immune system that is not able to fight off pathogens. Patients should be evaluated by their healthcare provider in order to further investigate the underlying cause."

"Normal wounds require the immune system to bring nutrients to repair damaged tissue," says Dr. Yadegar. "When this process is compromised, wounds are unable to heal properly, which signals a slow immune system. Delayed wound healing is indicative of a poorly-functional immune system, and should be evaluated by a healthcare provider."

Dr. Yadegar explains, "Long-term stress compromises the body's natural immunity, which can lead to higher risk of infections. While stress is inevitable in our fast-paced lives, taking steps to mediate stress can help. Whether meditation, exercise, or deep-breathing, it's important to tailor stress-relief to the individual in order to best improve their stress levels."

Heather Newgen

The rest is here:
Sure Signs Your Immune System Isn't as Strong as it Should Be Eat This Not That - Eat This, Not That

Read More...

Your Immune System Will Thrive With This Elderberry Hill Liquid Morning Multivitamin – Men’s Journal

Friday, August 19th, 2022

Mens Journal aims to feature only the best products and services. We update when possible, but deals expire and prices can change. If you buy something via one of our links, we may earn a commission.Questions? Reach us at shop@mensjournal.com.

Summers almost over guys. That means the Fall is right around the corner and the temps are gonna drop. Were about to enter the cold season. No one wants to deal with the cold, or anything even worse than that. We need to boost our immune systems in any way we can. And the Elderberry Hill Liquid Morning Multivitamin will be a big help.

The Elderberry Hill Liquid Morning Multivitamin is going to be a big help because of all the ingredients that each spoonful is chock full of. You got a lot of goodies in here that are perfect for getting that immune system going stronger than before. Ingredients thatll absorb into the bloodstream better because of its liquid form.

Whats in the Elderberry Hill Liquid Morning Multivitamin? Vitamins A, C, D3, E, Thiamin, Zinc, and all sorts of other goodies. All of which form together to not just help your immune system, but also help with the health of your hair, skin, and nails, as well as boost your energy levels. How can you beat that?

Even better is that this vitamin tastes pretty damn good too. Its almost like a little treat for yourself to get your morning started just right. And there are no sugars or GMOs in here. Its gluten and nut-free, so everyone, including vegans, can really enjoy this vitamin on the quest to boost your immune system.

Before the Fall comes along and brings the chill with it, we think you guys absolutely need to pick up the Elderberry Hill Liquid Morning Multivitamin. Its going to go down nice and smooth, getting your body prepped for the incoming season. Pick up a bottle now and get the prep started early. You wont regret it.

Get It: Pick up the Elderberry Hill Liquid Morning Multivitamin ($35) at Amazon

Check out the Daily Deals over at Amazon

For any questions or concerns you have about the Coronavirus, head on over to the CDC

Check out the great products and gear we recommend to Mens Journal readers

Related Links

The 4 Best Multivitamin For Men: Support Health and Performance

Look And Feel 10 Pounds Lighter With A Best Selling Colon Detox

6 Exogenous Ketone Supplements to Keep You Losing Weight In Ketosis

Visit link:
Your Immune System Will Thrive With This Elderberry Hill Liquid Morning Multivitamin - Men's Journal

Read More...

Can the monkeypox vaccine stop the current outbreak? : Goats and Soda – NPR

Friday, August 19th, 2022

A health-care worker prepares to administer a free monkeypox vaccine in Wilton Manors, Florida. The question: Can vaccination slow the outbreak? Joe Raedle/Getty Images hide caption

A health-care worker prepares to administer a free monkeypox vaccine in Wilton Manors, Florida. The question: Can vaccination slow the outbreak?

Finally, we have a glimmer of good news about monkeypox: The outbreaks in some countries, including the U.K., Germany and parts of Canada, are starting to slow down.

On top of that, the outbreak in New York City may also be peaking and on the decline, according to new data from the city's health department.

All these outbreaks are "far from extinguished," says infectious disease specialist Dr. Donald Vinh at McGill University in Montreal. But there are signs that, in some places, "they're a bit more under control than they had been."

For example, in the U.K., the number of new cases reported each day has steadily declined since late July, dropping from 50 daily cases to only about 25. (By contrast, here in the U.S., daily cases are still increasing. Since late July, the U.S. daily count has risen from 350 new cases to 450 cases.)

Some health officials credit the monkeypox vaccine and its quick rollout as the key factor that's slowing the spread of the virus in the U.K..

"Over 25,000 have been vaccinated with the smallpox vaccine, as part of the strategy to contain the monkeypox outbreak in the UK.," the U.K. Health Security Agency wrote on Twitter on Tuesday. "These 1000s of vaccines, given by the NHS to those at highest risk of exposure, should have a significant impact on the transmission of the virus."

Indeed, the U.K. and parts of Canada rolled out the vaccine in late May, weeks before doses became available in most U.S. cities.

But does the monkeypox vaccine have the ability to stop or curb the spread of the virus? To answer that question, we need to first understand a few basics about this vaccine.

What actually is the monkeypox vaccine? How does it work?

So the monkeypox vaccine is actually the smallpox vaccine. Maybe that sounds a bit strange, but in fact the two pox viruses are related. They're a bit like cousins.

Health-care workers used an earlier version of this vaccine to eradicate smallpox in the 1970s. So versions of this vaccine have been given to hundreds of millions of people over the past century. It has a long track record.

Back in the late 1980s, researchers started to notice something remarkable about this vaccine. During a monkeypox outbreak in the Democratic Republic of the Congo (then called Zaire), people who were immunized against smallpox were less likely to get monkeypox. They were protected. And not by just a little but by quite a bit. In a small study, published in 1988, researchers estimated the smallpox vaccine offered about 85% protection against monkeypox.

Now, the virus in this study was a different variant of monkeypox than the one circulating in the current international outbreak and that variant wasn't spreading primarily through sexual contact, as monkeypox is doing today. So we don't know how well these findings will translate to protection during the current outbreak. Which brings us to the next question.

How well does the vaccine protect against a monkeypox infection?

The short answer is: "We don't know," says infectious disease specialist Dr. Boghuma Titanji at Emory University.

There's no doubt the vaccine will offer some protection, Titanji says. "But right now, we still need studies in people to understand what level that protection actually is."

In North America and Europe, countries are primarily rolling out a vaccine called JYNNEOS, which was developed in the early 21st century. The goal with this vaccine is to increase its safety compared to the older vaccine, whose life-threatening complications, including encephalitis and skin necrosis, occurred in about 4 out of every million people vaccinated. That vaccine also could cause damaging skin lesions in people with eczema or weakened immune systems. (Note: There is a shortage of the JYNNEOS vaccine, and no doses have been shared with or sold to countries in Africa, which have experienced monkeypox outbreaks since the 1970s.)

Although older versions of the vaccine have been tested thoroughly in people, there has never been a large, clinical study to measure JYNNEOS's ability to protect against a monkeypox infection in people or to stop transmission of the virus.

What is known about the vaccine, in terms of its efficacy against monkeypox, comes from studies in macaques, and immunological studies in people, which demonstrated the vaccine triggers the production of monkeypox antibodies in people's blood.

"So we know that the vaccine does stimulate the immune system and people produce antibodies when they receive the vaccine," Titanji says, "but we don't have a clinical data in humans to actually tell us, 'Okay, that immune response translates to this level of protection against getting infected with monkeypox or reducing the severity of monkeypox disease if you do get infected.' "

And it's not a guarantee of protection. In this current outbreak, scientists have already begun to document breakthrough infection with this vaccine, the World Health Organization reported Thursday. "[This] is also really important information because it tells us that the vaccine is not 100% effective in any given circumstance," said Dr. Rosamund Lewis of WHO. "We cannot expect 100% effectiveness at the moment based on this emerging information."

And so when Titanji gives a person the JYNNEOS vaccine at her clinic, she is very clear about what the vaccine can and can't do. "I tell them, 'We do know that you're going to get some protection from this vaccine. Some protection is better than no protection. We also do know that the vaccine can reduce the severity of the disease if you do get infected. But we don't know for a fact that you would be completely protected from getting monkeypox.' "

Can this vaccine if given to the people who need it the most slow down the outbreak?

So the new data from the U.K. and Germany suggest that indeed this vaccine can curb the spread of monkeypox.

But Dr. Vinh at McGill University says it's way too soon to say the vaccine, alone, is the only factor contributing to the slow down in these countries. "No single measure is going to really be the solution here," says Vinh.

In addition to vaccination, people at high risk need to learn how they can protect themselves. And doctors have to learn how to spot monkeypox cases, he says.

Right now the percentage of monkeypox tests coming back positive is still incredibly high, Titanji says. "The positivity rate is close to 40%." And that means doctors are missing many cases. Specifically, they are still mistaking monkeypox for other sexually transmitted diseases such as syphyllis.

"I can tell you, from the lens of a clinician, that monkeypox is very, very easy to mistake for another infectious disease," she says.

Some people have had to visit clinics two or three times and even have been treated for another STD before the clinician suspects monkeypox.

"You really have to maintain a very high index of suspicion because some of the lesions are so subtle and the clinical presentation is so variable," she says. "At this phase of the outbreak, we should be over testing rather than under testing. If a doctor even remotely suspects monkeypox, they should be sending a test for it."

Otherwise people can't receive treatment for monkeypox and they can unknowingly spread it to others. And the outbreak will continue to grow while people wait to receive a vaccine and for that vaccine to begin working.

Visit link:
Can the monkeypox vaccine stop the current outbreak? : Goats and Soda - NPR

Read More...

Page 4«..3456..1020..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick